System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 7 citations

PubMed: 36679920 DOI: 10.3390/vaccines11010075

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland-Evaluation of Antibody Concentrations.

Vaccines (Basel) 11(1)

Authors: Paweł Zapolnik, Wojciech Kmiecik, Anna Nowakowska, Łukasz Jerzy Krzych, Henryk Szymański, Lidia Stopyra, Teresa Jackowska, Dorota Darmochwał-Kolarz, Artur Mazur, Hanna Czajka

Affiliations

  • College of Medical Sciences, University of Rzeszów, 35-315 Rzeszów, Poland.
  • St. Louis Provincial Specialist Children's Hospital, 31-503 Kraków, Poland.
  • Medical Diagnostics Laboratory, Regional Sanitary-Epidemiological Station, College of Medical Sciences, University of Rzeszów, 35-315 Rzeszów, Poland.
  • Department of Anaesthesiology and Intensive Therapy, Faculty of Medical Sciences, Medical University of Silesia, 40-055 Katowice, Poland.
  • Saint Hedwig of Silesia Hospital, 55-100 Trzebnica, Poland.
  • Department of Infectious Diseases and Paediatrics, Stefan Żeromski Specialist Hospital, 31-913 Kraków, Poland.
  • Department of Paediatrics, Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland.

Abstract

Tuberculosis (TB) was the predominant cause of death from a single infectious agent worldwide before the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Although TB vaccines have been successfully used for about 100 years, their full effect is still unknown. In previous studies, a reduced incidence and mortality from a coronavirus disease in TB-vaccinated populations were reported. In this article, we present the secondary analysis of a randomised controlled trial, reporting the results of a serological assessment evaluating the effect of the Bacillus Calmette-Guérin (BCG) vaccine on SARS-CoV-2. Participants-healthcare workers-were assessed 1-2 and 8 months after the second dose of the coronavirus disease 2019 (COVID-19) vaccine. We found no associations between antibody concentration, BCG revaccination, and additional characteristics, such as age, gender, or Body Mass Index. The effect of BCG vaccination on the immunological response against SARS-CoV-2 requires further research.

MeSH

Coronavirus, Sars-Cov-2, Vaccines, Incidence, Antibodies, Multiple Chronic Conditions, Vaccination, Covid-19, Pandemics, Severe Acute Respiratory Syndrome-Related Coronavirus, Infections

Cited by